规格
|
Alternate Agonists:
|
9-cis-retinoic acid, TTNPB, CD437, AM 580 |
Antagonists:
|
AGN 193109 |
Assay Entry:
|
Cell-based beta lactamase reporter gene |
Cell State:
|
Dividing Cells |
Druggable Target:
|
Nuclear Receptors |
Primary Agonist:
|
All-trans-retinoic Acid |
Product Line:
|
GeneBLAzer® |
Reporter Gene:
|
BLA (Beta-Lactamase) |
System Type:
|
GeneBLAzer™ |
Target Entry:
|
THRA, TR alpha, NR1A1 |
Detection Method:
|
Fluorescent |
储存
|
Shipping: Dry IceStorage: -80°C/Liquid NitrogenContains: TR alpha-UAS-bla HEK 293T cells (K1260) |
TR alpha-UAS-bla HEK 293T cells contain the ligand-binding domain (LBD) of the human Thyroid hormone receptor alpha(TR alpha) fused to the DNA-binding domain of GAL4 stably integrated in the GeneBLAzer®UAS-bla HEK 293T cell line. GeneBLAzer®UAS-bla HEK 293T cells stably express a beta-lactamase reporter gene under the transcriptional control of an upstream activator sequence (UAS). When an agonist binds to the LBD of the GAL4 (DBD)-TR alpha (LBD) fusion protein, the protein binds to the UAS, resulting in expression of beta-lactamase. TR alpha-UASbla HEK 293T 293 cells are functionally validated for Z' and EC50 concentrations of T3 Thryoid hormone. In addition, TR alpha-UAS-bla HEK 293T 293 cells have been tested for assay performance under variable conditions, including DMSO concentration, cell number, stimulation time, and substrate loading time (data available upon request). Additional testing data using alternate stimuli are also available.